Utility of Genomic Profiling Use for Targeted Therapy in a Phase I Setting Reveals that ESCAT I/II Actionable Targets are Associated with Improved Outcomes By Ogkologos - May 6, 2025 746 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CoPPO study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with... October 30, 2025 Take a Small Step April 21, 2021 Early cancer diagnosis and COVID-19: unpicking the impact of the pandemic December 20, 2022 FDA Approves Capmatinib for Metastatic NSCLC August 29, 2022 Load more HOT NEWS 9-Year-Old Has His Final Cancer Treatment After 3 Years – Breaks... BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... How Your Primary Care Provider Can Help You Throughout Your Cancer... FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who...
